Table 4. Hazard ratios (95% confidence intervals) for biochemical relapse after prostatectomy for established risk factors and nuclear ELAC2 expression in various scenarios.
| Model | Scenario 1 | Scenario 2 | Scenario 3 | Scenario 4 | |
|---|---|---|---|---|---|
| Variable | Category (N) | 8 232 | 8 362 | 8 485 | 8 473 |
| Gleason grade biopsy | ≥4+4 vs. 4+3 vs. 3+4 vs. ≤3+3 | 4.14 (3.63–4.69)*** | |||
| cT stage | T2c vs. T1c | 2.23 (1.73–2.71)*** | 2.05 (1.63–2.53)*** | ||
| Preoperative PSA level | ≥20 vs. 11–20 vs. 4–10 vs.<4 | 3.88 (3.19–4.74)*** | 2.98 (2.46–3.64)*** | 2.08 (1.71–2.53)*** | 1.91 (1.57–2.33)*** |
| Nuclear ELAC2 expression | Strong vs. mod. vs. weak vs. neg. | 1.58 (1.35–1.83)*** | 1.42 (1.22–1.64)*** | 1.33 (1.15–1.54)** | 1.29 (1.11–1.49)** |
| Gleason grade prostatectomy | ≥4+4 vs. 4+3 vs. 3+4 vs. ≤3+3 | 13.3 (10.9–16.1)*** | 6.48 (5.27–7.97)*** | 5.40 (4.36–6.70)*** | |
| pT stage | T4 vs. T3 vs. T2 | 3.14 (2.77–3.55)*** | 2.83 (2.48–3.22)*** | ||
| Surgical margin status | R1 vs. R0 | 1.40 (1.27–1.54)*** | 1.40 (1.27–1.54)*** | ||
| Nodal stage | N+ vs. N0 | 1.42 (1.24–1.63)*** |
Scenario 1 combines preoperatively available parameter (preoperative Gleason grade obtained on the original biopsy, clinical tumor (cT) stage, and preoperative PSA) with the postoperative ELAC2 expression at the negative, low (weak and moderate) and strong intensity levels. In scenario 2 the biopsy Gleason is replaced by the Gleason grade obtained on radical prostatectomy (RPE). In scenario 3, cT-stage is superseded by pathological tumor (pT) stage and surgical margin (R) status. In scenario 4 the lymph node (pN) stage is added. Asterisk indicate significance level: * p ≤ 0.05, ** p ≤ 0.001, and *** p ≤ 0.0001.